E-DRUG: Letter- Civil Society delegations to UNITAID Board, to CEO of Bristol-Myers Squibb
-----------------------------------------------------------------------
[According to FDA, on March 8, 2007, FDA granted approval for generic didanosine for oral solution (Pediatric Powder), 10 mg/mL, packaged in 2 gram and 4 gram containers, manufactured by Aurobindo Pharma Limited, of Hyderabad, India, allowing marketing in United States. This is a generic version of the already FDA approved Videx Pediatric Powder for Oral Solution, 10 mg/mL, manufactured by Bristol Myers Squibb.
http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm124264.htm.
Any comments?
Moderator]
The Civil Society delegations to UNITAID Board, representing
communities affected by HIV - related disease, TB and malaria, and NGOs working to
fight the three diseases, are today making public a letter addressed
to Mr Lamberto Andreotti, CEO of Bristol-Myers Squibb. Bristol-Myers
Squibb's plan to close a French factory is jeopardising the supply of
ddI 25mg, an antiretroviral for children and babies weighing under
10kg. The decision could leave up to 7000 babies without this vital
medicine. The Civil Society delegations are awaiting a response to the
below letter, which was sent to Mr Andreotti one week ago. Please
share the letter and information with your networks.